Chi­nook de­lays topline kid­ney con­di­tion da­ta; Elu­minex ropes in $40M+ in a Se­ries B

Chi­nook’s read­out of its Phase III ALIGN tri­al of atrasen­tan, a po­ten­tial treat­ment for chron­ic kid­ney dis­eases, could be de­layed by about three months, the com­pa­ny said in an SEC fil­ing. The tri­al is look­ing at atrasen­tan in pa­tients with im­munoglob­u­lin A nephropa­thy (IgAN), a con­di­tion that can cause kid­ney dis­ease.

The com­pa­ny said the FDA rec­om­mend­ed that it add 12 weeks to an in­ter­im analy­sis of pa­tients’ urine pro­tein lev­els or pro­tein­uria. That would push back the pro­tein­uria da­ta to the fourth quar­ter of this year. The com­pa­ny said it’s plan­ning to meet with the agency to dis­cuss the rec­om­men­da­tion. — Kather­ine Lewin

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN